Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy BridgeBio Pharma (BBIO) stocks in Canada

Learn how to easily invest in BridgeBio Pharma stocks.

BridgeBio Pharma is a biotechnology business based in the US. BridgeBio Pharma stocks (BBIO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $63.95 – a decrease of 10.12% over the previous week. BridgeBio Pharma employs 385 staff and has a trailing 12-month revenue of around $57 million.

How to buy shares in BridgeBio Pharma

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – BBIO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

BridgeBio Pharma stock price (NASDAQ:BBIO)

Use our graph to track the performance of BBIO stocks over time.

BridgeBio Pharma shares at a glance

Information last updated 2022-01-17.
Latest market close$11.46
52-week range$11.20 - $73.50
50-day moving average $34.13
200-day moving average $49.11
Wall St. target price$27.40
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.89

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy BridgeBio Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

BridgeBio Pharma price performance over time

Historical closes compared with the close of $11.46 from 2022-01-20

1 week (2022-01-14) -10.12%
1 month (2021-12-17) N/A
3 months (2021-10-20) -74.76%
6 months (2021-07-21) -81.40%
1 year (2021-01-21) -82.75%
2 years (2020-01-21) -64.44%
3 years (2019-01-17) N/A
5 years (2017-01-17) N/A

BridgeBio Pharma financials

Revenue TTM $57 million
Gross profit TTM $8.2 million
Return on assets TTM -42.63%
Return on equity TTM -1789.67%
Profit margin 0%
Book value $3.92
Market capitalisation $1.9 billion

TTM: trailing 12 months

BridgeBio Pharma share dividends

We're not expecting BridgeBio Pharma to pay a dividend over the next 12 months.

BridgeBio Pharma share price volatility

Over the last 12 months, BridgeBio Pharma's shares have ranged in value from as little as $11.2 up to $73.5. A popular way to gauge a stock's volatility is its "beta".

BBIO.US volatility(beta: 0.61)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BridgeBio Pharma's is 0.6079. This would suggest that BridgeBio Pharma's shares are less volatile than average (for this exchange).

BridgeBio Pharma overview

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.

Stocks similar to BridgeBio Pharma

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site